Vatelizumab (GBR 500) is a humanized monoclonal antibody antagonist of the VLA-2 (alpha2-beta1) integrin (a collagen-binding molecule expressed on activated lymphocytes).1 Vatelizumab was licensed to Sanofi for two Phase 2 clinical trials on multiple sclerosis (NCT02222948) (NCT02306811) but Sanofi decided not to pursue further vatelizumab as a potential therapy for relapsing-remitting multiple sclerosis (RRMS), following the results of a pre-planned interim analysis that revealed that the primary efficacy endpoint was not met. This decision was not due to safety concerns.

Glenmark decided to continue relicensing of GBR 500 after it is returned from Sanofi.

Vatelizumab’s mechanism of action is not known, but it is believed that it blocks the VLA-2 integrin on activated immune cells, leading to an interference with collagen-binding in inflammation sites, preventing them from entering the brain and spinal cord and thus stopping them from attacking and damaging myelin3, reducing the inflammatory cascade in multiple sclerosis process.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

  1. http://www.glenmarkpharma.com/novel-molecular-entities/research-pipeline
  2. http://www.genengnews.com/gen-news-highlights/glenmark-to-continue-developing-ms-candidate-after-sanofi-ends-up-to-663m-collaboration/81251920
  3. https://www.mssociety.org.uk/vatelizumab